How much profit has BioCorRx made this year?
BioCorRx has made -6.69 M USD this year.
BioCorRx Net Income 2024
BioCorRx Net Income
-6.69 M USD
Ticker
BICX
ISIN
US09073C2052
WKN
A1XERB
In 2024, BioCorRx's profit amounted to -6.69 M USD, a 77.47% increase from the -3.77 M USD profit recorded in the previous year.
The BioCorRx Net Income history
| YEAR | NET INCOME (undefined USD) |
|---|---|
| 2025e | - |
| 2024e | - |
| 2023 | - |
| 2022 | - |
| 2021 | - |
| 2020 | - |
| 2019 | - |
| 2018 | - |
| 2017 | - |
| 2016 | - |
| 2015 | - |
| 2014 | - |
| 2013 | - |
| 2012 | - |
| 2011 | - |
| 2010 | - |
| 2009 | - |
| 2008 | - |
BioCorRx Revenue, EBIT, Net Income US09073C2052 · A1XERB
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into BioCorRx, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by BioCorRx from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects BioCorRx’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of BioCorRx. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into BioCorRx’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing BioCorRx’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on BioCorRx’s growth potential.
BioCorRx Revenue, EBIT and net profit per share
| Date | BioCorRx Revenue | BioCorRx EBIT | BioCorRx Net Income |
|---|---|---|---|
| 2025e | 2.51 M undefined | 0 undefined | -7.74 M undefined |
| 2024e | 1 M undefined | 0 undefined | -6.69 M undefined |
| 2023 | 89,160 undefined | -3.74 M undefined | -3.77 M undefined |
| 2022 | 210,000 undefined | -4.7 M undefined | -4.37 M undefined |
| 2021 | 50,000 undefined | -5.37 M undefined | -5.28 M undefined |
| 2020 | 120,000 undefined | -7.49 M undefined | -3.47 M undefined |
| 2019 | 240,000 undefined | -5.56 M undefined | -6.04 M undefined |
| 2018 | 380,000 undefined | -4.38 M undefined | -6.51 M undefined |
| 2017 | 660,000 undefined | -2.89 M undefined | -29.71 M undefined |
| 2016 | 700,000 undefined | -2.18 M undefined | -5.9 M undefined |
| 2015 | 920,000 undefined | -5.12 M undefined | -4.67 M undefined |
| 2014 | 1.17 M undefined | -3.05 M undefined | -3.13 M undefined |
| 2013 | 710,000 undefined | -2.51 M undefined | -3.84 M undefined |
| 2012 | 870,000 undefined | -620,000 undefined | -890,000 undefined |
| 2011 | 770,000 undefined | -340,000 undefined | -410,000 undefined |
| 2010 | 140,000 undefined | -150,000 undefined | -150,000 undefined |
| 2009 | 0 undefined | -10,000 undefined | -10,000 undefined |
| 2008 | 0 undefined | -10,000 undefined | -10,000 undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2008 | 0 USD | -10,000 USD | -10,000 USD |
| 2009 | 0 USD | -10,000 USD | -10,000 USD |
| 2010 | 140,000 USD | -150,000 USD | -150,000 USD |
| 2011 | 770,000 USD | -340,000 USD | -410,000 USD |
| 2012 | 870,000 USD | -620,000 USD | -890,000 USD |
| 2013 | 710,000 USD | -2.51 M USD | -3.84 M USD |
| 2014 | 1.17 M USD | -3.05 M USD | -3.13 M USD |
| 2015 | 920,000 USD | -5.12 M USD | -4.67 M USD |
| 2016 | 700,000 USD | -2.18 M USD | -5.9 M USD |
| 2017 | 660,000 USD | -2.89 M USD | -29.71 M USD |
| 2018 | 380,000 USD | -4.38 M USD | -6.51 M USD |
| 2019 | 240,000 USD | -5.56 M USD | -6.04 M USD |
| 2020 | 120,000 USD | -7.49 M USD | -3.47 M USD |
| 2021 | 50,000 USD | -5.37 M USD | -5.28 M USD |
| 2022 | 210,000 USD | -4.7 M USD | -4.37 M USD |
| 2023 | 89,160 USD | -3.74 M USD | -3.77 M USD |
| 2024e | 1 M USD | 0 USD | -6.69 M USD |
| 2025e | 2.51 M USD | 0 USD | -7.74 M USD |
BioCorRx stock margins US09073C2052 · A1XERB
The BioCorRx margin analysis displays the gross margin, EBIT margin, as well as the profit margin of BioCorRx. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for BioCorRx.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the BioCorRx's sales revenue. A higher gross margin percentage indicates that the BioCorRx retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the BioCorRx's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the BioCorRx's total revenue generated. When comparing the revenue margin year over year, investors can gauge the BioCorRx's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the BioCorRx. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the BioCorRx's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
BioCorRx Margin History
| BioCorRx Gross margin | BioCorRx Profit margin | BioCorRx EBIT margin | BioCorRx Profit margin |
|---|---|---|---|
| 2025e | 59.63 % | 0 % | -308.95 % |
| 2024e | 59.63 % | 0 % | -666.85 % |
| 2023 | 59.63 % | -4,194.49 % | -4,224.89 % |
| 2022 | 95.24 % | -2,238.1 % | -2,080.95 % |
| 2021 | 80 % | -10,740 % | -10,560 % |
| 2020 | 25 % | -6,241.67 % | -2,891.67 % |
| 2019 | 66.67 % | -2,316.67 % | -2,516.67 % |
| 2018 | 55.26 % | -1,152.63 % | -1,713.16 % |
| 2017 | 50 % | -437.88 % | -4,501.51 % |
| 2016 | 75.71 % | -311.43 % | -842.86 % |
| 2015 | 83.7 % | -556.52 % | -507.61 % |
| 2014 | 81.2 % | -260.68 % | -267.52 % |
| 2013 | 77.46 % | -353.52 % | -540.85 % |
| 2012 | 54.02 % | -71.26 % | -102.3 % |
| 2011 | 48.05 % | -44.16 % | -53.25 % |
| 2010 | -7.14 % | -107.14 % | -107.14 % |
| 2009 | 59.63 % | 0 % | 0 % |
| 2008 | 59.63 % | 0 % | 0 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2008 | 59.63 % | 0 % | 0 % |
| 2009 | 59.63 % | 0 % | 0 % |
| 2010 | -7.14 % | -107.14 % | -107.14 % |
| 2011 | 48.05 % | -44.16 % | -53.25 % |
| 2012 | 54.02 % | -71.26 % | -102.3 % |
| 2013 | 77.46 % | -353.52 % | -540.85 % |
| 2014 | 81.2 % | -260.68 % | -267.52 % |
| 2015 | 83.7 % | -556.52 % | -507.61 % |
| 2016 | 75.71 % | -311.43 % | -842.86 % |
| 2017 | 50 % | -437.88 % | -4,501.51 % |
| 2018 | 55.26 % | -1,152.63 % | -1,713.16 % |
| 2019 | 66.67 % | -2,316.67 % | -2,516.67 % |
| 2020 | 25 % | -6,241.67 % | -2,891.67 % |
| 2021 | 80 % | -10,740 % | -10,560 % |
| 2022 | 95.24 % | -2,238.1 % | -2,080.95 % |
| 2023 | 59.63 % | -4,194.49 % | -4,224.89 % |
| 2024e | 59.63 % | 0 % | -666.85 % |
| 2025e | 59.63 % | 0 % | -308.95 % |
BioCorRx Aktienanalyse
What does BioCorRx do?
The company BioCorRx Inc is a US-American company that was founded in 2008 and is headquartered in Anaheim, California. BioCorRx specializes in the development and marketing of innovative treatment methods for alcohol and drug dependency. The history of BioCorRx began with the introduction of its flagship product, the BioCorRx Recovery Program, which is based on a novel medical technology called Naltrexone/Buprenorphine Implant. Unlike traditional methods of treating alcohol and drug addiction, which typically rely on medication and psychotherapeutic support, the BioCorRx Recovery Program is an implantable, long-term treatment system that continuously delivers the active ingredient Naltrexone or Buprenorphine into the patient's body. The idea behind this is that the active ingredients prevent withdrawal symptoms and thereby reduce the risk of relapse. In recent years, BioCorRx has expanded its product portfolio and expanded its business activities to new segments in order to further drive the company's growth. This includes, for example, the field of telemedicine services, which allow BioCorRx to offer its treatment technology and medical services through online communication. Telemedicine services such as virtual patient consultation or online group therapy programs are particularly in demand in times of COVID-19. Another focus of BioCorRx is the management of medical personnel. Studies have shown that good patient care and counseling heavily influence the success of treatment. BioCorRx has now also developed its own platform that eases and improves the management, training, and monitoring of medical staff. BioCorRx also utilizes the concept of franchise systems to market its products and services. The franchise system offers medical professionals and organizations working in the field of addiction treatment the opportunity to open their own BioCorRx clinic and offer the company's products and services in their local market. Each clinic is advised and supported by BioCorRx and must adhere to certain standards and quality criteria. In the future, BioCorRx plans to further diversify its product offering and develop new technologies to improve treatment options for alcohol and drug dependents. An example of such a technology is medication based on Ibogaine. BioCorRx has already started initial research in this direction and is actively working on pre-clinical studies. Overall, BioCorRx is a company that primarily focuses on innovative technologies for the treatment of addiction. The company has experienced substantial growth in recent years by expanding its product range and customer base, and focusing on the areas of telemedicine, personnel management, and franchise systems. With its forward-thinking technologies and strong emphasis on quality and patient satisfaction, BioCorRx is expected to continue playing an important role in addiction treatment in the years to come. BioCorRx ist eines der beliebtesten Unternehmen auf Eulerpool.com.Net Income Details
Understanding BioCorRx's Profit Margins
The profit margins of BioCorRx represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of BioCorRx's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.
Year-to-Year Comparison
Evaluating BioCorRx's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.
Impact on Investments
BioCorRx's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.
Interpreting Profit Fluctuations
When BioCorRx’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.
Frequently Asked Questions about BioCorRx stock
How has the profit developed compared to last year?
The profit has increased by 77.47% compared to last year increased
What impact do the earnings have on the shareholders?
An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.
How does BioCorRx publish its earnings?
BioCorRx publishes its earnings in the form of quarterly or annual reports.
Which financial indicators are included in the quarterly or annual reports?
The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.
Why is it important for investors to know the earnings of BioCorRx?
The profits of BioCorRx are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.
How can one learn more about the earnings of BioCorRx?
You can learn more about the earnings of BioCorRx by reviewing the quarterly or annual reports or following the company presentations.
How much dividend does BioCorRx pay?
Over the past 12 months, BioCorRx paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, BioCorRx is expected to pay a dividend of 0 USD.
What is the dividend yield of BioCorRx?
The current dividend yield of BioCorRx is .
When does BioCorRx pay dividends?
BioCorRx pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of BioCorRx?
BioCorRx paid dividends every year for the past 0 years.
What is the dividend of BioCorRx?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is BioCorRx located?
BioCorRx is assigned to the 'Health' sector.
Wann musste ich die Aktien von BioCorRx kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of BioCorRx from 11/4/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/4/2024.
When did BioCorRx pay the last dividend?
The last dividend was paid out on 11/4/2024.
What was the dividend of BioCorRx in the year 2023?
In the year 2023, BioCorRx distributed 0 USD as dividends.
In which currency does BioCorRx pay out the dividend?
The dividends of BioCorRx are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von BioCorRx
Our stock analysis for BioCorRx Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of BioCorRx Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
